Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16054385 | 1.00 | SLC6A5 (0.49) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL9885941 | 1.00 | SLC6A5 (0.49) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL7167413 | 1.00 | SLC6A5 (0.49) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL26624603 | 0.94 | SLC6A5 (0.59) | SLC6A5FAAHEPHX2ALDH1A1 | |
| SCHEMBL13279668 | 0.93 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL19138238 | 0.93 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL17203886 | 0.93 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL9664371 | 0.93 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL20956613 | 0.93 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL19138227 | 0.93 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160192678-A1 | FEED FOR LACTATING RUMINANTS | BENEMILK OY (FI) | 2016-07-07 | — | — | US | claimed |
| EP-4489718-B1 | METHOD FOR ENCAPSULATING A HYDROPHOBIC COMPOUND, SUSPENSION OF STRUCTURED LIPID PARTICLES ACCORDING TO THIS METHOD, AND USES OF SAID SUSPENSION | SEDERMA SA (FR) | 2026-03-11 | — | — | EP | disclosed |
| EP-4489718-A1 | METHOD FOR ENCAPSULATING A HYDROPHOBIC COMPOUND, SUSPENSION OF STRUCTURED LIPID PARTICLES ACCORDING TO THIS METHOD, AND USES OF SAID SUSPENSION | SEDERMA (FR) | 2025-01-15 | — | — | EP | disclosed |
| CN-115243668-B | Cosmetic composition for treating sagging skin and treatment | 赛德玛公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118695841-A | Method for encapsulating hydrophobic compounds, structured lipid particle suspension according to the method and use of said suspension | 赛德玛公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024133788-A1 | METHOD FOR OBTAINING AN EXTRACT OF PLANT ORIGIN, A COMPOSITION CONTAINING IT AND ITS COSMETIC USE | SEDERMA (FR) | 2024-06-27 | — | — | WO | disclosed |
| EP-3145943-B1 | PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES IN PARTICULAR COSMETIC USES | SEDERMA SA (FR) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023169963-A1 | METHOD FOR ENCAPSULATING A HYDROPHOBIC COMPOUND, SUSPENSION OF STRUCTURED LIPID PARTICLES ACCORDING TO THIS METHOD, AND USES OF SAID SUSPENSION | SEDERMA (FR) | 2023-09-14 | — | — | WO | disclosed |
| EP-2367852-B1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | SEDERMA SA (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-116615178-A | Cosmetic tetrapeptides, compositions and uses | 赛德玛公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2006071850-A2 | METHOD OF USING LASER INDUCED INJURY TO ACTIVATE TOPICAL PRODRUGS | RELIANT TECHNOLOGIES, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060110413-A1 | Novel Molecules dervied from noraporphine | SEDERMA (FR) | 2006-05-25 | — | — | US | disclosed |
| US-6974799-B2 | Compositions containing mixtures of tetrapeptides and tripeptides | SEDERMA S.A.S. (FR) | 2005-12-13 | — | — | US | disclosed |
| WO-2005102266-A1 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER | SEDERMA, SAS (FR) | 2005-11-03 | — | — | WO | disclosed |
| EP-1555999-A2 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING KOMBUCHA | Sederma S.A.S. (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005048968-A1 | COMPOSITIONS CONTAINING MIXTURES OF TETRAPEPTIDES AND TRIPEPTIDES | SEDERMA (FR) | 2005-06-02 | — | — | WO | disclosed |
| EP-1534682-A1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | Sederma S.A.S. (FR) | 2005-06-01 | — | — | EP | disclosed |
| US-20040132667-A1 | Compositions containing mixtures of tetrapeptides and tripeptides | SEDERMA S.A.S (FR) | 2004-07-08 | — | — | US | disclosed |
| WO-2004024695-A1 | NOVEL MOLECULES DERIVED FROM NORAPORPHINE | SEDERMA S.A.S. (FR) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004012650-A2 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING KOMBUCHA | SEDERMA SAS (FR) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060110413-A1 | Novel Molecules dervied from noraporphine | DPM1, NPM1, TYR | SLC6A5 4284/4885NOD1 1629/4885ITGB3 3858/4885 |
| US-20040132667-A1 | Compositions containing mixtures of tetrapeptides and tripeptides | MC1R, SGTA, TPP1 | SLC6A5 4093/4885NOD1 3102/4885ITGB3 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.